 |
|
|
| |
Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451
|
| |
| |
Reported by Jules Levin EASL 2011 Berlin March 31-Apr 2
A Corsa, M Robinson, H Yang, B Peng, G Cheng, B Schultz, O Barauskas, M Hung, X Liu, C Yang, Y Wang, G Rhodes,
R Pakdaman, M Shen, C Sheng, C Kim, W Delaney
Gilead Sciences Foster City, CA USA
References
1. E. Lawitz; J. M. Hill; T. C. Marbury; M. Rodriguez-Torres; M. P. DeMicco; J. Quesada; P. Shaw; S. C. Gordon; M. J. Shelton; D. H. Coombs; J. Zong; A. Bae; K. A. Wong; H. Mo; E. Mondou; K. R. Hirsch; W. E. Delaney. Three-Day, Dose-Ranging Study of the HCV NS3 Protease Inhibitor GS-9451. Hepatology Vol 52, S1 p714A
|
| |
|
|
|
|
|
